{"id":"NCT03573297","sponsor":"AbbVie","briefTitle":"A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features","officialTitle":"A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-15","primaryCompletion":"2022-09-05","completion":"2022-09-05","firstPosted":"2018-06-29","resultsPosted":"2023-09-28","lastUpdate":"2023-09-28"},"enrollment":901,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder","Mania","Depression"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Double-Blind Cariprazine 3.0 mg/day","type":"EXPERIMENTAL"},{"label":"Double-Blind Cariprazine 1.5 mg/day","type":"EXPERIMENTAL"},{"label":"Double-Blind Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open Label Treatment","type":"EXPERIMENTAL"}],"summary":"1\\) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety of cariprazine at a target dose of 1.5 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features who were initially stabilized on a target dose of 3.0 mg/day","primaryOutcome":{"measure":"Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period","timeFrame":"From Week 16 to Week 55","effectByArm":[{"arm":"Double-Blind Placebo QD","deltaMin":null,"sd":null},{"arm":"Double-Blind Cariprazine 1.5 mg QD","deltaMin":null,"sd":null},{"arm":"Double-Blind Cariprazine 3.0 mg QD","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5745"},{"comp":"OG000 vs OG002","p":"0.6308"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":108,"countries":["United States","Bulgaria","Malaysia","Poland","Puerto Rico","Russia","Serbia","South Korea","Taiwan","Thailand","Ukraine"]},"refs":{"pmids":[],"seeAlso":["https://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":896},"commonTop":["HEADACHE","AKATHISIA","INSOMNIA","WEIGHT INCREASED","NAUSEA"]}}